Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population - Wikidata - awgldk - TriplyDB

Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population

Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population

http://www.wikidata.org/entity/Q28266112

about

Genomic/Epigenomic Alterations in Ovarian Carcinoma: Translational Insight into Clinical Practice DNA repair targeted therapy: The past or future of cancer treatment?Integration of Population-Level Genotype Data with Functional Annotation Reveals Over-Representation of Long Noncoding RNAs at Ovarian Cancer Susceptibility Loci.Inherited Mutations in Women With Ovarian Carcinoma Ten Important Considerations for Ovarian Cancer Screening Counselling framework for moderate-penetrance cancer-susceptibility mutations.RAD51B in Familial Breast Cancer Genetic characterization of early onset ovarian carcinoma.Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer.Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor.Increasing sensitivity to DNA damage is a potential driver for human ovarian cancer Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature.Epidemiology of ovarian cancer: a review.Characterisation of the novel deleterious RAD51C p.Arg312Trp variant and prioritisation criteria for functional analysis of RAD51C missense changes.Gene-panel testing of breast and ovarian cancer patients identifies a recurrent RAD51C duplication.BRCA mutation in ovarian cancer: testing, implications and treatment considerations.Molecular mechanisms of human papillomavirus-related carcinogenesis in head and neck cancer.Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk.Hereditary breast and ovarian cancer: new genes in confined pathways.Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.Therapeutic targeting and patient selection for cancers with homologous recombination defects.Frequency of germline PALB2 mutations among women with epithelial ovarian cancer.Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.Germline multi-gene hereditary cancer panel testing in an unselected endometrial cancer cohort.BRCA mutations in the manifestation and treatment of ovarian cancer.Anticipated health behaviour changes and perceived control in response to disclosure of genetic risk of breast and ovarian cancer: a quantitative survey study among women in the UK.XPAT: a toolkit to conduct cross-platform association studies with heterogeneous sequencing datasets.Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach.Thiopurine-induced mitotic catastrophe in Rad51d-deficient mammalian cells.Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls.Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study.Contribution of germline deleterious variants in the RAD51 paralogs to breast and ovarian cancers.Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells.High expression of Rad51c predicts poor prognostic outcome and induces cell resistance to cisplatin and radiation in non-small cell lung cancer.Evaluating the breast cancer predisposition role of rare variants in genes associated with low-penetrance breast cancer risk SNPs.Detection of Germline Mutations in Patients with Epithelial Ovarian Cancer Using Multi-Gene Panels: Beyond BRCA1/2.Approaches for Identifying Novel Targets in Precision Medicine: Lessons from DNA Repair.Prevalence of germline BRCA mutations among women with carcinoma of the peritoneum or fallopian tube.

P2860

Q26740622-906F136B-796F-421B-AEE3-F6DAD4DA9806 Q26768679-72CC700D-9F1B-49CB-8E37-90189B043D98 Q30275132-8DA3767C-FC0A-4A45-A07C-3D66F200EAEE Q30353433-CFC0A718-769D-48A1-AF69-B4A88EBCFF3B Q33850463-B21E2731-55E1-464E-8AA4-2426EEDB61B7 Q33911135-6C94F138-CA97-4155-B459-BBDC5BACB103 Q36009422-0949439C-AB01-47CC-A55C-2B3D69DEAB27 Q36908973-1BBB4F5F-6137-49FA-BB5F-35D53DC92D1A Q36915151-33BB4E95-48A5-402D-BC4D-522E22A36040 Q37138952-10E08991-A8BE-41DB-879E-979C87E2BA90 Q37580300-3BE4DF7D-3086-4343-9D54-B207A2611D5A Q37661436-47F8D3AB-E0A3-43A7-A7B8-D8B04B9DA42E Q37720438-45C82495-6AA3-4BE8-901B-A0E2D8DDECA3 Q38614203-E99DC3AE-9892-4948-93F9-53F693D7FCBD Q38627916-6EAFAA12-738B-47FF-9565-5FD0B75A569E Q38644661-E14C4CB2-3CED-4246-A72B-B6E8E7E2B138 Q38723429-926FD8B5-4168-40CC-9182-EBCCEB0D857C Q38845261-DA9EA978-E0A2-4B51-906E-07C96D65EB20 Q38925408-E4F4FD0B-5963-40EC-8667-7B1525D40872 Q38979257-E84FD3AD-BE21-41CE-8C1D-ED4260A7340B Q39251572-0CD69D99-5668-4CD9-A15E-75927E2AD83B Q40580115-78A335E2-8DDD-4D68-AE9C-CCF65E938870 Q41691425-17458112-BA03-4604-A8AB-8708705AFF50 Q42619703-40F5D275-6CD8-43E9-8705-B7B2A000F26E Q47134293-D0510F1F-A92F-47A6-A67F-02F9EA238F2D Q47185863-82B72F0D-060A-4375-B6D6-E0C522D47C7A Q47222722-7BE5C2C2-A2A8-4F3E-8C17-16F640F3ECE9 Q47397232-08B9A67D-8C3C-4185-819C-CB2D076BC21C Q47748271-46554F8B-1CCA-40AC-97E8-B0B30AEE90F9 Q47828874-F80D3FA3-9BD7-46EF-BF97-C49C6DB26A09 Q47958061-EAE42C48-F774-4401-BA01-F0963F77D5D6 Q48097657-E6932073-FA1F-4DA9-BC41-53A6B826F680 Q48124146-02872B29-3611-409D-ABC6-894A5B557500 Q49153890-B6327C8E-A70C-41CC-B20D-DAA930281960 Q50050350-F4D6246A-65D2-4EFE-82B5-DB37DE8616F9 Q50094892-75CBA8C3-9FEC-4BC7-A8E5-414F9D1FFD40 Q51800946-C6593F56-9F81-4AF1-8287-C298F4904168 Q55397998-E77347CA-29F9-4537-9540-12714A5258F0

P2860

Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population

http://www.wikidata.org/entity/Q28266112

description

2015 nî lūn-bûn

@nan

2015 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Contribution of Germline Mutat ...... arian Cancer in the Population

@ast

Contribution of Germline Mutat ...... arian Cancer in the Population

@en

Contribution of Germline Mutat ...... arian Cancer in the Population

@nl

type

label

Contribution of Germline Mutat ...... arian Cancer in the Population

@ast

Contribution of Germline Mutat ...... arian Cancer in the Population

@en

Contribution of Germline Mutat ...... arian Cancer in the Population

@nl

prefLabel

Contribution of Germline Mutat ...... arian Cancer in the Population

@ast

Contribution of Germline Mutat ...... arian Cancer in the Population

@en

Contribution of Germline Mutat ...... arian Cancer in the Population

@nl

P1433

Q28266112-CBC7D503-735E-4566-92F5-0A4B49EC8228

P1476

Q28266112-5EE94C7B-1A03-4F49-8DDF-447CD0FCAF5C

P2093

Q28266112-01868884-2FCC-468F-ACE0-2B99AB4EF453

Q28266112-0ED2B2F6-708D-474F-BC5E-0DB75E7D9F9F

Q28266112-1FEBE9E8-8139-4E63-A445-108900B9C0BE

Q28266112-214097C2-62A1-4AF8-9925-91CACF471172

Q28266112-22CD9ADA-35A5-4FC0-AB08-E1AC648B061C

Q28266112-25067737-4B55-415A-9019-8C1748E17590

Q28266112-2649D22E-26DA-4D00-B9D8-B63871E957B0

Q28266112-32AF5134-7A2F-4A6A-92CA-C9B3D928C3BA

Q28266112-41B66A7E-459E-4361-9AC8-4F9B43791528

Q28266112-4C011E1B-8CB9-44E1-B81D-883474B454C4

P2860

Q28266112-005D639F-DDCB-4461-8B5C-99BDAB2CDF90

Q28266112-02C4EAA9-39F4-4DED-A25C-64ADC18F0836

Q28266112-0DC2E448-5783-4CB0-AA7D-E7AEE6D95EA9

Q28266112-0E75EAF8-D9AE-419D-B39C-C4035FF3A702

Q28266112-17994278-AA75-4B44-A415-1FDAB7AB3645

Q28266112-1AA88248-1236-4651-A825-9E4906F62A17

Q28266112-1E056C43-82D2-428E-A427-740DD246F3CD

Q28266112-2561ECEA-690A-4300-8580-BC5F0A14A352

Q28266112-399967A1-1582-4F85-84AC-87F549BEDBEB

Q28266112-3AEB6816-DE8C-42DC-9703-410AF1066BAD

P304

Q28266112-8DD4FFF2-2BBA-4990-8124-FA085C0C845B

P31

Q28266112-2B099239-F5E4-464E-8322-D7F86996BA3D

P3181

Q28266112-C98065E6-FAEF-48F3-9EF3-80450BCA8652

P356

Q28266112-19B489C0-8A9D-4B2F-BF9B-FC2A7B22A7D6

P407

Q28266112-6825E392-0A41-45D3-8754-0954901B8241

P433

Q28266112-A6E3A5EA-348B-4946-9A88-83C85BE12BC3

P478

Q28266112-3E22C378-0282-40D2-BD5A-E56DC41FE122

P50

Q28266112-22E5E089-54D3-4C5A-BBCA-10F1FB1E273E

Q28266112-25FA4606-D150-4033-BD29-ABA7D3C75C72

Q28266112-448FD941-9DF3-453A-9E39-C3645F93D751

Q28266112-53845F96-F591-4C31-9C44-87FCE9E3642D

Q28266112-659D6578-D038-4EF7-97BA-E1AB857813B6

Q28266112-7FD070E6-9A8A-43D8-A807-3971E47BCE14

Q28266112-86012B7E-F295-453F-816F-E86BAAC176C4

Q28266112-97434B7C-D018-43B4-A599-2B8F0AF88E51

Q28266112-9E939AEA-0381-44B8-8B87-6E11F97B88AD

Q28266112-B31B2548-781B-4CDC-BFE9-AD5E33EDFC1E

P577

Q28266112-F56A3ABD-F029-45F9-80C8-58542D11B163

P698

Q28266112-719A8678-E6D9-40E7-B5AA-D2DE51CEF42D

P921

Q28266112-8D4ED532-67C5-485D-AE66-BC2995E24C05

P932

Q28266112-C9C03717-2373-4E99-8F44-1B790669EEBC

P3181

P356

JCO.2015.61.2408

P1433

Journal of Clinical Oncology

P1476

Contribution of Germline Mutat ...... arian Cancer in the Population

@en

P2093

Brooke L Fridley

http://www.w3.org/2001/XMLSchema#string

Christopher Anderson

http://www.w3.org/2001/XMLSchema#string

Christopher K Edlund

http://www.w3.org/2001/XMLSchema#string

Claus K Høgdall

http://www.w3.org/2001/XMLSchema#string

David Conti

http://www.w3.org/2001/XMLSchema#string

Ed Dicks

http://www.w3.org/2001/XMLSchema#string

Ellen L Goode

http://www.w3.org/2001/XMLSchema#string

Honglin Song

http://www.w3.org/2001/XMLSchema#string

Ian J Jacobs

http://www.w3.org/2001/XMLSchema#string

Jacek Gronwald

http://www.w3.org/2001/XMLSchema#string

P2860

Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing

Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer

Domain mapping of the Rad51 paralog protein complexes

Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk

Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas

The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data

A method and server for predicting damaging missense mutations

A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1

Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland

Germline mutations in RAD51D confer susceptibility to ovarian cancer

P304

2901-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4628365

http://www.w3.org/2001/XMLSchema#string

P356

10.1200/JCO.2015.61.2408

http://www.w3.org/2001/XMLSchema#string

P407

P433

26

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P50

Aleksandra Gentry-Maharaj

Estrid Høgdall

Susanne Krüger Kjaer

Lara Sucheston-Campbell

P577

2015-09-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26261251

http://www.w3.org/2001/XMLSchema#string

P921

P932

4554751

http://www.w3.org/2001/XMLSchema#string